ALEXANDRIA: Egypt’s Rameda Pharmaceutical has acquired requests to export Anviziram tablets, that are used to deal with sufferers with the brand new coronavirus, to Saudi Arabia, Kuwait, Iraq and Yemen, however wants a authorities approval first, its CEO advised Reuters.
The corporate stated earlier this month it had began manufacturing Anviziram, the generic equal of the Japanese antiviral Avigan, and had additionally acquired an approval from the Egyptian Drug Authority to fabricate Remedsivir, a Gilead Sciences Inc. antiviral used for treating COVID-19.
Rameda, which listed 49 p.c of its shares on the Egyptian alternate final 12 months, has produced portions sufficient Anviziram tablets to cowl “acceptable numbers of sufferers within the Egyptian market,” stated its CEO Amr Mursi.
The corporate is offering the drug to the Egyptian well being ministry for use in hospitals. Mursi stated it will be out there to the general public earlier than the top of July, including its industrial worth was nonetheless being negotiated.
He expects extra requests from Gulf nations to import Anviziram, however the firm’s response is dependent upon the approval of the Egyptian authorities.
“We’ll talk about this with them subsequent week to see whether or not we will export or not,” Mursi stated.